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INTRODUCTION 
 
                      Lung cancer is the leading cause of cancer mortality 
worldwide .Upto 90% of all lung cancers are classified as Non small cell 
lung carcinoma and majority present with advanced disease. Tumor 
classification establishes the foundation for tumor diagnosis and patient”s 
therapy. The recent updated WHO classification was developed in 
2015,which is not very different from the historical one. The recent 
classification also divides lung carcinomas into two major groups: 
small and non small cell carcinomas. The latter includes Squamous 
cell carcinoma,adenocarcinoma,large cell carcinomas,sarcomatoid 
carcinomas and mixed. The most common histological type is 
Squamous cell carcinoma,but the incidence of Adenocarcinoma is 
increasing recently. 
Our improved understanding of tumorigenesis have led to newer 
and more directed,targeted therapies.Epidermal growth factor receptor 
mutations constitute one of the major subsets among those molecular 
aberrations.The protein coded by the gene plays a key role in cell 
proliferation,survival and other hallmarks of cancer and it is also 
susceptible to pharmacological inhibition for therapeutic purposes. 
Epidermal growth factor receptor mutation has a critical role in first, 
second, and third line therapy and also serve as prognostic factor, since 
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patients with these mutations have better clinical outcomes. Therapies 
targeted to these molecular lesions offer the prospect for tumor control 
and selectivity with less toxicity than conventional chemotherapy. 
                     The present study is done on a better method to identify 
those Non small cell lung carcinoma who would most likely to benefit 
from treatment with EGFR targeted therapy.Non small cell lung 
carcinoma patients can be screened for Epidermal growth factor receptor 
mutations as a routine to predict which patient will respond to epidermal 
growth factor receptor inhibitor. 
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                                            AIMS AND OBJECTIVES 
 
1. To determine that screening for EGFR expression would be of 
great value in designing treatment protocols in Non small cell lung 
carcinoma. 
2. To assess the EGFR mutation status in various histological types of 
Non small cell lung carcinoma with reference to age,sex and 
personal habits. 
3. To conclude that histopathological diagnosis supplemented by 
Immunohistochemical markers aid in targeted therapies since 
EGFR targeted therapy has increased survival rate than 
conventional chemotherapy. 
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REVIEW OF LITERATURE 
Lung Cancer has emerged as a common cancer in India and is a 
leading cause of cancer related mortality. Tuberculosis, tarring of roads, 
the 1918 influenza epidemic, anthracosis, and anthracosilicosis – are now 
considered to account for only a minimal fraction of cases. Exposure to 
asbestos, polycyclic aromatic hydrocarbons, arsenic, nickel, and 
chromium compounds; bis(chloromethyl)ether (BCME),chloromethyl 
methyl ether (CMME),vinyl chloride; radiation  and other occupational 
agents undoubtedly account for some of the cases(1,2).A  linear correlation 
exists between the severity of the changes leading to carcinoma and the 
amount of cigarette consumption. Approximately 10–15% of cases of 
lung carcinomas occur in non-smokers. Pulmonary fibrosis also leads to 
malignancy, through a preceding stage of atypical proliferation of the 
terminal bronchiolar epithelium. 
                      Most lung cancers are of considerable size when first 
detected, and about 60% are incurable as a result of extensive local 
spread and/or distant metastases.Clinical presentation is mainly due to 
bronchial obstruction which includes cough, weight loss, pain, increased 
sputum production, hemoptysis,  malaise, fever, and those resulting from 
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paraneoplastic manifestations. Peripherally located lesions are 
asymptomatic until they reach a sufficient size to ulcerate into a bronchus 
or to involve the pleural space. Carcinomas located in the superior 
pulmonary sulcus result in a clinical picture peculiar to their location, 
known as Pancoast syndrome,characterized by pain in the distribution of 
the ulnar nerve and is often associated by Horner syndrome,possibly due  
to involvement of the sympathetic chain. Occasionally lung carcinoma 
presents as a solitary circumscribed mass (‘coin lesion’) on the chest x-
ray film of an asymptomatic individual. About 35–50% of pulmonary 
coin lesions in adults represent lung carcinoma3. They are sometimes 
associated with extrapulmonary manifestations not related to the presence 
of metastatic disease.. 
MOLECULAR PROFILING OF LUNG CANCER 
Newer techniques, particularly immunohistochemistry (IHC) and 
molecular biology, have produced a large amount of information on 
tumor histogenesis, differentiation, and proliferation that has been widely 
applied to tumor subtyping(4,5). 
Prior to WHO 2004 classification ,there was no therapeutic 
implication of distinguishing histological subtypes such as 
adenocarcinoma and squamous cell carcinoma.Therefore tumors other 
than small cell carcinomas are put together as non small cell 
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carcinomas,without regard for specific histologic typing.For years, based 
on the available chemotherapeutic regimens, lung cancer was classified 
for clinical purposes into “small cell” and “non–small cell” carcinoma. 
With the recent development of targeted therapies, this classification is 
revised with the understanding that more specific subtyping of the non–
small cell group is required. For example, Patients with adenocarcinoma 
or non small cell carcinoma not otherwise specified, had a better survival 
rate than those with squamous cell carcinoma when treated with 
pemetrexed.18 Patients with squamous cell carcinoma have a life 
threatening complication of hemorrhage when treated with 
bevacizumab18. The Epidermal growth factor receptor is one of these 
targets. As a cellular receptor with tyrosine kinase activity, the protein 
encoded by this gene plays a role in cell proliferation, survival and other 
hallmarks of cancer, and it is also susceptible to pharmacological 
inhibition for therapeutic purposes. Many papers were published showing 
significant response to targeted therapy when an EGFR mutation is 
present in lung carcinomas. Because therapeutic targets are being 
increasingly identified outside of adenocarcinoma, a firm diagnosis of 
squamous cell carcinoma is a must. 
                  Lung cancer is generally diagnosed at a locally advanced or 
metastatic stages. The progression free survival and overall survival still 
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remains low. Thus the research on molecular profiling of lung cancer has 
been on the run today.  
The discovery of specific genetic alterations that are subjective to 
tyrosine kinase inhibitors has necessitated revision of the older approach 
and is gradually leading to the development of a molecular genetic 
classification for lung tumors.(6,7) 
               Investigators have identified multiple processors that are 
responsible to the contribution of tumor progression and growth. Through 
molecular diagnostics tumor cells maybe distinguished depending on the 
presence or absence of receptor proteins, mutations, and fusion 
rearrangements. For the past decade, various markers have  been 
identified in Non small cell lung carcinomas. Most  common and most 
studied are EGFR,ALK,HER2,RET,KRAS.(8,9) 
The presence of activating mutations of the EGFR gene correlates 
with a better response to treatment with tyrosine kinase inhibitors; current 
recommendations for EGFR testing in lung cancer extends to all cases 
harboring an adenocarcinoma component because of the high prevalence 
of this mutation for this histologic subtype10.Patients with the ALK 
rearrangement have also been identified with adenocarcinoma 
morphology11. K-RAS mutations are also present in about 15% to 30% of 
lung adenocarcinomas and are regarded as a marker of resistance to 
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tyrosine kinase inhibitors12. Adenocarcinomas with either EGFR or ALK 
rearrangements are preferentially seen in non smokers and develop in the 
lung peripheral parenchyma.18Adenocarcinomas with KRAS mutations 
are preferentially seen in smokers and commonly in hilar regions, same as 
squamous cell carcinoma and small cell carcinoma.18 As more genetic 
targets are identified and correlated with response to targeted therapies, 
the more important the molecular testing will become in the classification 
of lung cancer. 
EGFR MUTATIONS                     
 EGFR-The ERB family is a group of receptors on cell surface in 
non small cell lung cancer, which controls major intracellular signalling 
pathways. It is the first receptor tyrosine kinase to be linked directly to 
tumors13.Binding to its specific ligands induces the receptor dimerization 
and auto phosphorylation of the intracellular tyrosine kinase domain, 
activating downstream signalling pathways.  These pathways are 
responsible for proliferation, differentiation, motility, angiogenesis and 
ultimate survival of cancer cells. There are major receptors like EGFR or 
ERRB1,B2,B3,B4 also termed as HER1,HER2,HER3,HER4.All of them 
play an important role in cell signalling. Once activated the EGFR then 
phosphorylates its substrates resulting in downward chain reaction. The 
two major downsignalling pathways are MAPK-ERK pathway 
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responsible for cell proliferation and P13K-AKT-Mtor pathway 
determining cell survival14. 
    EGFR mutations occur in approximately 10% to 15%  of non small 
cell lung carcinomas. Over expression and structural alterations of EGFR 
are frequent in a number of human malignancies(lung, colorectal, head 
and neck,pancreatic,renal,bladder,breast,,ovarian,oesophageal,gastric, 
prostate carcinomas, glioblastomas, and uterine malignant mixed 
mullerian tumor)15,16,17More than 20 to 30 % of adenocarcinomas have 
EGFR mutations. In squamous cell carcinoma the incidence of mutation 
is less. These mutations increase the tyrosine kinase activity, which leads 
to the activation of transcription factors and cell proliferation.. EGFR 
overexpression and amplification are also observed in patients with non 
small cell lung cancer18. 
The identification of EGFR as an oncogene has lead to the 
development of EGFR–targeted cancer therapies. EGFR inhibitors can be 
mainly divided into two classes:monoclonal antibodies against the 
extracellular domain of EGFR, such as cetuximab; and small molecule 
tyrosine kinase inhibitors that target the kinase domain such as erlotinib 
and geftinib.19,20 A major breakthrough in the field of EGFR-targeted 
therapy was the discovery of somatic mutations in the tyrosine kinase 
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domain of EGFR gene in lung adenocarcinomas that are associated with 
good clinical response to EGFR–tyrosine kinase inhibitors. 
The most commonly acquired mutations are in the tyrosine kinase 
domain of EGFR gene, which are EXON 19 deletions and 21 L858R 
point mutations. Approximately 90% of the mutations occur in these two 
hot spots.21,22Mutation specific antibodies for EGFR-L858R and EXON 
19 are available for the detection of these mutations. The sensitivity to 
small molecule epidermal growth factor receptor inhibitor is greatest with 
the L858R mutation and the EXON 19 deletion mutations. Other 
mutations, example EGFR T790M in EGFR has developed resistance to 
EGFR inhibitors. Combination of small molecule EGFR inhibitors and 
mutation specific inhibitors for other mutations are under trial for the 
treatment of lung cancers with secondary resistance developed for the 
other mutations in EGFR18. 
Due to these developments, tissue samples are no longer managed 
for diagnosis alone but also for immunohistochemical staining and 
molecular testing for potential targeted therapy. This approach is 
important for small biopsies and cytology, because approximately 70% of 
lung cancers are inoperable when presenting and molecular targeted 
therapies that require molecular testing are primarily administered to 
patients with advanced non small cell lung carcinoma. The introduction 
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of molecular testing for EGFR and KRAS mutations, as well as the 
routine use of immunohistochemistry, has revealed that that some 
adenocarcinomas have a pseudosquamous morphology .In case of doubts, 
the diagnosis should be confirmed by immunohistochemistry.  
WHO CLASSIFICATION: 
The most widely accepted histologic classification of lung tumors 
is that proposed by the World Health Organization (WHO)-2015 
CLASSIFICATION18. 
1. EPITHELIAL TUMORS :  
ADENOCARCINOMA 
Lepidic adenocarcinoma 
Acinar adenocarcinoma 
Papillary adenocarcinoma 
Solid adenocarcinoma 
Invasive mucinous adenocarcinoma 
 Mixed invasive mucinous and non-mucinous adenocarcinoma 
Colloid adenocarcinoma 
Fetal adenocarcinoma 
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Enteric adenocarcinoma 
Minimally invasive adenocarcinoma 
            Non mucinous 
            Mucinous 
Preinvasive lesions 
            Atypical adenomatous hyperplasia 
            Adenocarcinoma in situ 
Non mucinous 
Mucinous 
SQUAMOUS CELL CARCINOMA 
           Keratinising Squamous cell carcinoma 
           Non-Keratinising Squamous cell carcinoma 
           Basaloid squamous cell carcinoma 
           Preinvasive lesion  
Squamous cell carcinoma in situ 
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NEUROENDOCRINE CARCINOMA 
           Small cell carcinoma 
                            Combined small cell carcinoma 
           Large cell Neuroendocrine carcinoma 
                            Combined Large cell Neuroendocrine carcinoma 
           Carcinoid tumors 
                            Typical  Carcinoid 
                            Atypical Carcinoid 
           Preinvasive Lesion 
                            Diffuse idiopathic pulmonary Neuroendocrine cell 
hyperplasia 
LARGE CELL CARCINOMA 
ADENOSQUAMOUS CARCINOMA 
PLEOMORPHIC CARCINOMA 
SPINDLE CELL CARCINOMA 
GIANT CELL CARCINOMA 
CARCINOSARCOMA 
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PULMONARY BLASTOMA 
OTHER AND UNCLASSIFIED CARCINOMAS 
               Lymphoepithelioma like carcinoma 
               NUT carcinoma 
SALIVARY GLAND  TYPE TUMORS 
               Mucoepidermoid carcinoma 
               Adenoid cystic carcinoma 
               Epithelial-Myoepithelial carcinoma 
               Pleomorphic adenoma 
PAPILLOMAS 
               Squamous papilloma 
                             Exophytic 
                             Inverted 
               Glandular papilloma 
               Mixed squamous cell and glandular papilloma 
ADENOMAS 
               Sclerosing pneumocytoma 
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               Alveolar adenoma 
               Papillary adenoma 
               Mucinous cystadenoma 
               Mucous gland adenoma 
II. MESENCHYMAL TUMORS: 
Pulmonary Hamartoma 
Chondroma 
PEComatous tumors 
               Lymphangioleiomyomatosis 
               PEComa,benign 
                        Clear cell tumor 
               PEComa,malignant 
Congenital peribronchial myofibroblastic tumor 
Diffuse pulmonary lymphangiomatosis 
Inflammatory Myofibroblastic Tumor 
Epithelioid Hemangioendothelioma 
Pleuropulmonary Blastoma 
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Synovial sarcoma 
Pulmonary artery intimal sarcoma 
Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation 
Myoepithelial tumors 
          Myoepithelioma 
          Myoepithelial carcinoma 
III.LYMPHANGIOHISTIOCYTIC TUMORS 
Extranodal marginal zone lymphoma of mucosa associated lymphoid 
tissue(MALT LYMPHOMA) 
Diffuse large B-cell lymphoma 
Lymphomatoid granulomatosis 
Intravascular large B-cell lymphoma 
Pulmonary Langerhan’s cell histiocytosis 
Erdheim-Chester disease 
 IV.TUMORS OF ECTOPIC ORIGIN 
Germ cell tumors  
        Teratoma,mature 
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        Teratoma,immature 
Intrapulmonary Thymoma  
Melanoma  
Meningioma ,NOS 
V.METASTATIC TUMORS 
 
 
EPITHELIAL TUMORS : BRONCHOGENIC - ALVEOLAR 
CARCINOMAS : 
Bronchogenic carcinomas of non–small cell  (nonneuroendocrine) 
type arise from bronchial lining epithelium or from the lining of alveolar 
walls and represent the most common form of lung cancer. These tumors 
typically involve individuals in the sixth or seventh decade of life23. 
Symptoms of bronchogenic carcinoma will depend on the tumor’s 
anatomic distribution. Cough, hemoptysis, dyspnea, wheezing, or 
pneumonia wil be seen in centrally located lesions. Peripheral lesions will 
be symptomatic only when the tumor reaches a larger size and invades 
adjacent structures. In certain subtypes of carcinoma, such as so-called 
bronchioloalveolar carcinoma , bronchorrhea (expectoration of large 
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amounts of mucus) maybe the presenting symptom24.When the tumors 
reach an advanced stage, they may invade adjacent structures such as the 
pleura, chest wall, and/or mediastinum, giving rise to symptoms of 
pleuritic pain, the Pancoast syndrome, or superior vena cava 
syndrome.Paraneoplastic syndromes such as inappropriate secretion of 
antidiuretic hormone, Cushing syndrome, or acromegaly can occur in few 
cases25. In some instances, adenocarcinomas can be associated with other 
nonneoplastic lung conditions such as fibrotic lung disease, tuberculosis, 
bronchiectasis, or pneumonia. 
 IMAGING STUDIES                    
 Adenocarcinoma may present as a solitary pulmonary mass with a 
well-circumscribed  or poorly defined appearance on imaging. When the 
tumors grow along the pleural surface, they resemble a pleural 
mesothelioma. Thin-section computed tomography scan may prove 
helpful in case of small and peripheral tumors, because it may display  air 
bronchograms or air bronchiolograms in approximately 65% of cases 
which help in distinguishing carcinomas from benign lesions26. MRI 
helps in assessing chest wall invasion, because an increased signal 
intensity will exist on T2-weighted images27.Squamous cell carcinomas 
are more often central tumors growing within the main bronchus. The 
typical radiographic presentation is that of total or partial bronchial 
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obstruction which may lead to pneumonia. Intractable pneumonia in an 
adult should always be closely investigated for the possibility of 
underlying malignancy. 
 
ADENOCARCINOMA:  
Adenocarcinoma of the lung is the most frequent lung cancer 
occurring in Japan and some Asian countries. They are more common in 
males. Primary pulmonary adenocarcinoma is defined as a malignant 
epithelial neoplasm showing features of glandular differentiation, and 
with mucin production and pneumocyte expression. Lung 
adenocarcinoma can show a variety of distinctive growth patterns that 
include acinar, papillary, lepidic (bronchioloalveolar), solid, and 
cribriform. On the basis of the predominant pattern, histological 
subtyping is made. 
 GENETICS:                                    
          TP53 alteration, most commonly in the form of point mutation and 
sometimes homozygous deletion, is found in about 50% of 
adenocarcinoma, and is correlated with cigarette smoking; G–T 
transversions are the footprints of the effects of tobacco 
carcinogens28.P16/CDKN2A inactivation, due to biallelic deletion, 
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iatrogenic mutations or promoter hypermethylation, is very frequent, and 
results in disruption of the RB pathway28. Another common genetic 
alteration is allelic loss of 3p, implicating many tumor suppressor genes, 
such as FHIT/FRAB3 and RASSF1A28. STK11/LKB1 (the gene implicated 
in Peutz–Jeghers syndrome) is commonly mutated28. KRAS mutation is 
found in about 30% of cases of pulmonary adenocarcinomas29. Atypical 
bronchioloalveolar hyperplasia also reveals the presence of KRAS 
mutations and is said to be an indicator of poor prognosis in 
adenocarcinoma29.EGFR (epidermal growth factor receptor) gene 
mutations occur at a significantly higher frequency in non-small cell lung 
carcinomas from East Asians than from non-Asians (30% vs 8%), from 
women than from men (59% vs 26%), from non-smokers than from 
smokers (66% vs 22%), and in adenocarcinomas compared with other 
non-small cell carcinoma histologies (49% vs 2%)30.The KRAS mutation 
and EGFR mutation in pulmonary adenocarcinomas are mutually 
exclusive, in that the former occurs in tumors of smokers and the latter 
occurs in tumors of non smokers. Recently, 3–5% of pulmonary 
adenocarcinomas show specific translocations involving the ALK 
(anaplastic lymphoma kinase) gene, with the fusion partner being usually 
the EML4 gene31. The ALK-translocated pulmonary adenocarcinomas 
show the following characteristics: occurrence in non smokers or light 
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smokers, younger patient age, and lack of mutations in the EGFR, KRAS, 
and TP53 genes.These tumors show a solid, acinar, or cribriform growth 
pattern, often with prominent extracellular and intracellular mucin, 
sometimes with signet ring morphology. In contrast to anaplastic large 
cell lymphoma, the ALK protein expression level is often low, such that 
conventional immunohistochemical techniques may give false-negative 
staining32.In this minor subset of adenocarcinomas,many studies of 
interest  have been on the go because target therapy is available for the 
ALK tyrosine kinase; a recent study shows that crizotinib (an orally 
available small molecule inhibitor of ALK) can produce a response rate 
of 57%32. 
MACROSCOPY: 
Grossly, most adenocarcinomas present as poorly circumscribed 
gray-yellow lesions with central scarring fibrosis associated with 
anthracotic pigmentation and pleural puckering, arising in the periphery 
of the bronchial tree. They may be single or multiple, If they secrete 
abundant mucin, they have a gelatinous, glairy appearance. Well 
differentiated adenocarcinoma often penetrates the pleura to disseminate 
into the pleural cavity, frequently producing pleural  effusion. On the 
other hand poorly differentiated adenocarcinoma directly invades the 
thoracic wall through fibrous adhesion. Occasionally, a small peripheral 
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adenocarcinoma spreads massively into the pleural space and coats both 
pleural layers so as to closely simulate the appearance of diffuse 
mesothelioma (pseudomesotheliomatous carcinoma)33.Adenocarcinoma 
also frequently involves the lymphatics, but lymph nodes with metastases 
may not enlarge.The incidence of intrapulmonary metastasis is highest in 
adenocarcinoma, occurring not only through the lymphatics and blood 
vessels but also through the airway. Hematogenous metastasis is also 
frequently seen in many organs.     
MICROSCOPY   : 
Adenocarcinoma was subdivided histologically into acinar 
(tubular), papillary, bronchioloalveolar, and solid  carcinoma with mucus 
formation by the old WHO  classification18.  The WHO classification was 
recently updated in 2015. The morphological signs of glandular 
differentiation are formation of tubules or papillae and secretion of 
mucin. Grading of adenocarcinoma into well, moderately, and poorly 
differentiated tumors depends on the degree and extent of glandular 
differentiation present, as well as the degree of cytologic atypia34. Well-
differentiated neoplasms are characterized by a proliferation of well-
formed glands lined by atypical cells that infiltrate the surrounding 
stroma, whereas poorly differentiated tumors grow as solid sheets of 
tumor cells with scant or poorly formed glandular structures and are 
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recognized as adenocarcinomas on the basis of the demonstration of 
intracellular mucin production . The glands in well-differentiated 
adenocarcinoma are generally composed of tall columnar or mucinous 
epithelium with ample clear or eosinophilic cytoplasm, basally situated 
nuclei, prominent nucleoli, and frequent mitotic figures. In moderately 
differentiated adenocarcinoma, the glandular proliferation is more 
haphazardly distributed, with more intervening stromal reaction and 
inflammation, and the tumor cells show more atypia and frequent mitotic 
figures.         
 The majority (approximately 80%) of lung adenocarcinomas fall 
into the “mixed” type, which has been defined by the WHO 200418   with 
a mixed array of histologic growth patterns (acinar, papillary, 
bronchioloalveolar, solid with mucin) . This fact acquires clinical 
relevance because of the increased demands on pathologists for 
accurately subclassifying lung cancer for selection of treatment. Accurate 
classification of the mixed type of adenocarcinoma can be extremely 
subjective, particularly in small biopsy samples or cytology specimens, 
and may be of little help for discriminating among responders and 
nonresponders for the new targeted therapies35.  
A modification to the classification of lung adenocarcinoma has 
been proposed recently by the IASLC/ATS/ERS,36 which addresses 
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mainly the diagnostic criteria and definition of bronchioloalveolar 
carcinoma as proposed in the 2004 WHO schema. The changes include 
1)discontinuing the terms bronchoalveolar adenocarcinoma and mixed 
subtype adenocarcinoma; 2)adding adenocarcinoma in situ as a 
preinvasive   lesion,  to  join  with   atypical  adenomatous   hyperplasia; 
3) adding minimally invasive adenocarcinoma; 4)classifying invasive 
adenocarcinomas according to the predominant subtype after 
comprehensive histological subtyping by estimating the various subtypes 
percentage; 5)using  the term lepidic for a non invasive component 
present as a part of invasive adenocarcinoma; 6) Introducing the term 
Invasive mucinous adenocarcinoma previously known as mucinous 
bronchoalveolar  carcinoma  excluding  the tumors  that  meet  the  
criteria for adenocarcinoma in situ or minimally invasive 
adenocarcinoma;  7) discontinuing the subtypes of clear cell and signet 
ring adenocarcinoma and describing this as a feature even when small 
amount is present; 8)discontinuing the term mucinous 
cystadenocarcinoma  and including it under colloid 
adenocarcinoma36.This WHO classification allowed accurate 
classification of this tumor only  on resection specimens, thus essentially 
eliminating this diagnostic category in small biopsy  samples and 
cytology. In the new proposal, the term “bronchioloalveolar carcinoma” 
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has been eliminated and the concepts of “adenocarcinoma in situ” and 
“minimally invasive adenocarcinoma” have been introduced .       
 
 HISTOLOGICAL CLASSIFICATION 
1)LEPIDIC ADENOCARCINOMA            
Bronchioloalveolar carcinoma is characterized by a neoplastic 
proliferation of bland pneumocytes(type II pneumocytes or clara cells) 
that grows exclusively along the lining of the alveolar walls, a pattern 
referred to as “lepidic.”37 The cells show mild cellular atypia and some 
mitotic activity but are restricted to the alveolar walls without any 
evidence of infiltration into the interstitium . Grossly the lesions may be 
single, multifocal, or diffuse. When the tumor is diffuse, the lesion may 
simulate pneumonia both grossly and radiographically. Two principal 
histologic types have been described: (1) The mucinous type is 
characterized by a proliferation of fairly uniform columnar, mucin-
secreting cells that completely replace the normal alveolar lining; (2) the 
non mucinous type is characterized by round to cuboid cells with scant 
cytoplasm and prominent, hyperchromatic nuclei with a “hobnail” 
configuration. Few cases show intranuclear inclusions. Similar 
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morphology is seen in adenocarcinoma in situ and minimally invasive 
adenocarcinoma. 
 Lepidic predominant adenocarcinoma diagnosis can be made if the 
tumor :1)invades lymphatics, blood vessels and pleura;2)exhibits tumor 
necrosis;3)invasive component >5mm is seen;4)shows spread through air 
spaces in the surrounding lung parenchyma. 
Invasion is defined by :1)histological subtypes other than a lepidic 
pattern;2) myofibroblastic stroma admixed with invasive tumor 
cells;3)vascular or pleural invasion; and 4) spread through air 
spaces38.Lepidic predominant pattern can also be seen in invasive 
mucinous adenocarcinoma and metastatic tumors to the lung,in which the 
diagnosis should not be made as lepidic adenocarcinoma. 
2)ACINAR ADENOCARCINOMA 
Glands with a central luminal space surrounded by tumor cells  is 
the characteristic feature. The tumor cells and/or glandular spaces contain 
mucin. Acinar structures are composed of rounded aggregates of tumor 
cells with peripheral nuclear polarization and central cytoplasm without a 
clear lumen. Cribriform pattern is a feature of acinar adenocarcinoma 
which in case if present has a poor prognosis39. 
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3)PAPILLARY ADENOCARCINOMA 
Neoplastic cells are seen in a glandular pattern with a central 
fibrovascular core. If the tumor acini or alveolar spaces are filled with 
papillary structures, the tumor pattern is classified as papillary 
adenocarcinoma, which helps to distinguish it from tangential sectioning 
of alveolar walls in an area of lepidic adenocarcinoma. Micropapillary 
variant is composed of tumor cells growing in papillary tufts forming 
florets that lack fibrovascular core. The tumor cells are small and 
cuboidal, with variable nuclear atypia. Ring like glandular structures may 
float within alveolar spaces. Psammoma bodies are common. Vascular 
and stromal invasion is seen. This variant is highly aggressive with 
increased incidence of metastasis40. 
4)SOLID ADENOCARCINOMA 
Sheets of polygonal tumor cells with loss of specific pattern are 
included in this variant. If the tumor is 100% solid, intracellular mucin 
should be present in  5 tumor cells in each of two high power fields and 
confirmed with histochemical stains for mucin36.Tumors previously 
classified as Large cell carcinoma that have pneumocyte marker 
expression even if mucin is absent are now classified as solid 
adenocarcinoma. Solid adenocarcinoma should be distinguished from 
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squamous cell carcinomas and large cell carcinomas ,both of which may 
contain intracellular mucin in few cells. 
Noguchi et al. classified small sized adenocarcinomas (less than 2 
cm in diameter) into two groups41, one group showing replacement 
growth and the other showing destructive growth of preexisting alveolar 
structures. Both of them are subdivided into three histological types as 
follows: 
Histologic Classification of Small-Sized Adenocarcinoma (Noguchi’s 
Classification)  
Replacement type (lepidic type) adenocarcinoma  
1)Type A: Localized bronchioloalveolar carcinoma (LBAC) 
2) Type B: LBAC with focal collapse of the alveolar structure 
3) Type C: LBAC with focus of fibroblastic proliferation  
Non replacement type (nonlepidic type) adenocarcinoma 
4) Type D: Poorlydifferentiated adenocarcinoma  
5)Type E: Tubular or acinar adenocarcinoma  
6)Type F: True papillary adenocarcinoma     
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1)TypeA: Localized Bronchioloalveolar Carcinoma 
Tumors of this variant are solitary and show growth by 
replacement of alveolar lining cells with minimal or mild thickening of 
the alveolar septa . The tumors do not have fibrotic foci. Histologically, 
they are well-differentiated localized bronchioloalveolar carcinomas, and 
the individual cells resemble Clara cells, type II pneumocytes, or goblet 
cells. 
2)TypeB:Localized Bronchioloalveolar Carcinoma with Foci of 
Alveolar Structural Collapse  
This variant resembles that of type A, showing a replacement 
growth pattern except that these type tumors contain fibrotic foci due to 
alveolar collapse. The fibrosis in this tumor is due to alveolar collapse 
without cellular growth. Elastin stain helps in the diagnosis. 
3)Type C: Localized Bronchioloalveolar Carcinoma with Foci of 
Active Fibroblastic Proliferation 
These type of tumors show a replacement growth pattern, but foci 
of active fibroblastic proliferation are detectable. This type constitutes the 
common pattern of small-sized adenocarcinoma. These actively 
proliferating fibroblasts are absent in the foci of alveolar collapse seen in 
type B. The nuclei of tumor cells in the foci of active fibroblastic 
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proliferation are larger and show more  atypia than those in the peripheral 
replacement region.Thus it is also known as focally (or minimally) 
invasive bronchioloalveolar carcinoma.42,43 
4)TypeD: Poorly Differentiated Adenocarcinoma  
These tumors are composed of predominant solid growth, and 
papillary and tubular growth patterns are minor components . 
Histologically, it resembles as that of ‘‘solid adenocarcinoma with 
mucin’’in the third WHO classification44. Therefore, it is sometimes 
difficult to distinguish these tumors from large cell carcinoma 
histologically. The distinction between the cancer and the noncancerous 
parenchyma is evident grossly. 
5)Type E: Tubular Adenocarcinoma  
This tumor type consists of acinar, tubular, and cribriform 
structures, and tumor cells with a signet ring appearance maybe present. 
They are classified as‘‘acinar adenocarcinoma’’ in the third WHO 
classification44.They are proposed to originate from or differentiate 
toward bronchial gland cells. The tumor boundary is always distinct. 
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6)Type F:Papillary Adenocarcinoma with a Compressive Growth 
Pattern  
This  Papillary variant  is expansive and destructive .This type is 
classified as "papillary adenocarcinoma’’ in the third WHO 
classification44 .They also show a clear distinction between the tumor and 
the uninvolved  parenchyma  macroscopically.  
Noguchi’s classification is well correlated with patient prognosis 
and CT findings. Type A and B tumors have an extremely favorable 
prognosis. Compared to replacement-type adenocarcinomas, type D, 
E,and F tumors have a poor prognosis and the 5-year survival rate of 
patients with type D tumors is 50%. The  histologic replacement growth 
pattern corresponds to the ground glass opacity feature on CT scan. 
Hence, type A, B, and C tumors and other non replacement-type tumors 
can be distinguished on the basis of CT findings. These histologic and 
radiologic findings suggest malignant progression of peripheral type 
adenocarcinomas from atypical adenomatous hyperplasia (AAH), i.e., 
types A and B to type C. Loss of heterozygosity for chromosomes on 
which important suppressor genes are located accumulates, and activated 
expression of matrix metalloproteinase(MMP)-2 increases during the 
course of malignant progression from type A to typeC45.Thus type A and 
B adenocarcinomas with an  extremely favorable prognosis are 
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candidates for limited surgery such as wedge resection or 
segmentectomy, or careful followup alone. 
Cytological classification 
Adenocarcinoma cells are supposed to differentiate toward any of 
the various epithelial cells seen in the bronchus and bronchioloalveoli. 
For the sake of  convenience ,we subclassify adenocarcinoma of the lung 
into the following six cytologic types46:  
             1. Bronchial surface cell type with little or no mucus production  
             2. Goblet cell type  
             3. Bronchial gland cell type 
             4. Clara cell type 
             5. Type II alveolar epithelial cell type   
             6. Mixed cell type or indeterminate cell type             
The direction of differentiation can be assumed by light 
microscopic observation and is confirmed by IHC findings. .Hence, 
classifying the tumor not only from its histologic structure but also from 
cytologic appearance (i.e., the direction  of tumor cell differentiation) is 
important for reaching a better understanding of the biological and 
clinical behavior of a given tumor. Many adenocarcinomas that are less 
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than 1.5 cm in diameter are composed of tumor cells of a single cell type, 
whereas larger tumors consist of two cell types or more, because of 
metaplastic changes in tumor cells from one cell type to another, such as 
Clara cell type to mucus-producing cells. 
1.Bronchial surface cell type with little or no mucus production. 
This cell type arises either in cartilage-bearing bronchus showing 
endobronchial polypoid growth or in the distal airway47. It is composed of 
tall columnar cells arranged in a papillary and tubular fashion, which 
resemble ciliated columnar cells, although no cilia are visible. 
2. Goblet cell type.  
The tumor cells resemble goblet cells of the bronchial epithelium, 
in which the cytoplasm is filled with mucus, displacing the nuclei to the 
basal portion. They are mostly arranged in a bronchioloalveolar pattern 
with a lobar pneumonia-like gross feature.     
3.  Bronchial gland cell type.  
Cuboidal or polygonal cells filled with mucin are arranged in acini, 
tubules or ductal structures, cribriform patterns, or solid nests. 
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4.Clara cell type. 
Peg-shaped cells or low columnar cells with tongue-shaped 
projections into the spaces are arranged in a papillary pattern. In precise, 
they form (1) tubular structures in and around the central or subpleural 
fibrotic focus; (2) papillary structures in the midzone of the tumor; and 
(3) a bronchioloalveolar pattern at the periphery or advancing border of 
the tumor46.The nuclei are oval with a thick nuclear membrane, granular 
chromatin, and inconspicuous nucleoli in malignancy with mild atypia; 
The nuclei are irregular and pleomorphic with prominent nucleoli  and an 
increase in mitosis are noted in tumors with marked atypia. Intranuclear 
eosinophilic inclusion bodies are commonly seen48.  
Clara cell–type adenocarcinoma is the most common type of 
adenocarcinoma, accounting for more than 50% of cases49. Clara cell 10-
kd protein (CC10) is the dominant product from Clara cells50, and it has 
been proposed to have immunomodulatory and anti-inflammatory 
activity. Many Studies have done to show downregulation of CC10 
contributing to carcinogenesis51.Distinction from tumor cells of Type II 
alveolar epithelial type is difficult by light microscopy,and at times both 
the types may be present in a single tumor. 
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5.TypeII alveolar epithelial cell type.  
Cuboidal to low columnar cells  with a dome-shaped free cell 
border and vacuolated cytoplasm are arranged in papillary or 
bronchioloalveolarpatterns. Macroscopically the tumor is solitary and 
nodular and rarely diffuse .Surfactant apoprotein is the specific 
immunohistochemical marker52, but  it is also positive in tumors  of the 
Clara cell type, the bronchial surface epithelial cell type with little or no 
mucus, or the bronchial gland cell type53.   
Cytologic subtyping is often difficult in poorly differentiated 
adenocarcinoma. 
 
VARIANTS OF ADENOCARCINOMA 
1.Invasive mucinous adenocarc inoma 
Invasive mucinous adenocarcinoma has been introduced as a new 
category in the IASLC/ATS/ERS  classification replacing the term 
mucinous bronchioloalveolar because of distinct radiological, and 
pathological findings. Microscopically  goblet cells with abundant 
intracytoplasmic mucin and basal nucleus arranged in acinar, lepidic, 
papillary or micropapillary pattern is seen. Nuclear atypia is minimal. 
Mucin pools are seen in the alveolar spaces. If there is ≥10% of non 
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mucinous component, the tumor is  called as mixed mucinous and non 
mucinous adenocarcinoma, with description of the different components. 
The tumor is typically positive for CK7 and CK20,negative for TTF154. 
2.Colloid adenocarcinoma 
 The Alveolar spaces are filled with abundant extracellular mucin  
and destroy their walls .Mucin pools enlarge and dissect the lung 
parenchyma  ,and  tall columnar cells with goblet cell morphology in a 
lepidic pattern are seen floating in the mucin matrix. Marked nuclear 
atypia and pseudostratification are seen. Grossly they present as soft 
,gelatinous, well demarcated peripheral nodular masses55.Colloid 
adenocarcinoma cells express intestinal markers CK20 ,CDX2,MUC2. 
They differ from invasive adenocarcinoma by the  mucin pools replacing 
the alveolar architecture and only scattered tumor cells seen lining the air 
spaces. 
3.Fetal adenocarcinoma 
They resemble fetal lung and they occur in much younger patients 
than other adenocarcinomas. Grossly they present as a solitary well 
demarcated mass with a bulging tan to white cut surface. On microscopy 
they are composed of complex glandular structures composed of 
glycogen rich non ciliated cells which simulates a developing epithelium 
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in the pseudoglandular phase of the fetal lung. They are subdivided into 
low and high grade. 
Low grade fetal adenocarcinomas have mild atypia with morule 
formation and surrounded by a loose fibromyxoid stroma56.High grade 
displays marked atypia, no morule formation, necrosis, with a transition 
to conventional adenocarcinoma56.They express TTF1 ,ERβ and β-
catenin57. More  than 90% of low grade tumors express Chromogranin A 
and Synaptophysin whereas they are positive in only 50% of high grade 
tumors56.High grade tumors more commonly express α-fetoprotein, 
Glypican-3 and SALL456.They are differentiated from metastatic 
endometrial adenocarcinoma by the clinical findings and negativity for 
estrogen and progesterone receptor. 
4.Enteric adenocarcinoma 
Grossly, they present as well demarcated peripheral lung masses 
with foci of yellow punctate necrosis. Primary pulmonary 
adenocarcinoma with enteric differentiation was first proposed by Tsao et 
al58.Histological resemblance to colorectal malignancy is the hallmark. 
They are composed of eosinophilic tall columnar cells with a brush 
border and vesicular nuclei arranged in acinar, cribriform or papillary 
structures. Central geographic necrosis may be seen. The diagnosis is 
confined to tumors with ≥50% of enteric  morphology. They are 
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considered as lung primary only if intestinal primary is excluded since 
both share the same immunohistochemical profile. 
MINIMALLY INVASIVE ADENOCARCINOMA: 
They are small, solitary with a predominant lepidic pattern(≤3cm) 
and seen as an incidental finding. The invasive component is ≤ 5 mm in 
its largest dimension59.The invasive component is to be composed of 
histological subtypes other than the lepidic pattern. Minimally invasive 
adenocarcinoma is excluded if the tumor invades lymphatics, blood 
vessels, air spaces, or pleura, and if contains necrosis,  or spread thro 
alveolar spaces. It is usually non-mucinous, but mucinous component can 
occur. Minimally invasive adenocarcinoma is staged as T1a. Grossly they 
present in peripheral location with central fibrosis, anthracotic 
pigmentation and pleural puckering. 
 
SQUAMOUS CELL CARCINOMA 
 Squamous cell carcinoma is a malignant epithelial tumor with 
keratinisation or internuclear bridges, or morphologically undifferentiated 
non small cell carcinoma that express IHC markers of squamous 
differentiation. 
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ETIOLOGY: 
They are strongly associated with smoking. Arsenic exposure is 
considered to be a significant risk factor. 
GENETICS 
Squamous cell carcinomas are characterized by gene copy number 
alterations including gain/amplification of chromosomes 
3q(SOX2,TP63),7p(EGFR) and 8p(FGFR1),as well frequent deletion of 
cheomosome 9p(CDKN2A)60.Two pathways are involved by genetic 
alterations. One is the oxidative stress response pathway, includes 
mutations in NFE2L2,KEAP1, OR CUL3.Other is implicated in 
squamous differentiation and includes amplification and over expression 
of SOX2 and TP63  mutations and focal deletions in FOXP161.Only few 
cases harbor EGFR and KRAS mutations62. 
MACROSCOPY: 
Both the Keratinising and Non keratinizing types arise in the main 
or lobar bronchus. But one study proposed that peripheral locations are 
far more common63. They are soft and friable and may present with 
necrosis and cavitation commonly. Intraluminal polypoid masses 
infiltrating the bronchial wall is seen in centrally located tumors. 
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MICROSCOPY: 
 Keratinising type presents with internuclear bridges, 
keratinisation, pearl formation depending on the differentiation. In Non 
keratinizing type Immunohistochemistry is required to confirm the 
squamous phenotype.i.e., diffuse positivity for squamous markers 
p40,p63,CK5/6 and negativity for TTF1.Architectural and cytological 
subtyping used in 2004 WHO classification64 is not in use now since 
other than basaloid morphology, others have no prognostic or molecular 
significance. 
Metastasis from urothelial carcinoma show similar features with 
non keratinizing type .They may also show positivity for CK7,p63,P40 
but they are more often GATA3, UROPLAKIN 3 and CK 20 positive64.In 
the lung, squamous cell carcinoma may entrap alveolar pneumocytes, 
which sometimes may be misdiagnosed as adenosquamous carcinoma. 
Squamous metaplasia with cytological atypia in diffuse alveolar damage 
may also be misinterpreted as squamous carcinoma, but features of 
alveolar damage like hyaline membranes, diffuse alveolar septal 
connective tissue proliferation with pneumocytic hyperplasia will point 
towards a metaplastic process. Distinguishing primary lung carcinomas 
from a metastasis in patients with prior history of  squamous cell 
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carcinoma of other areas is quite difficult. Comparison of TP53 
mutation/p53 immunostaining status between lung and prior tumor of 
other sites,HPV testing,p16 Immunohistochemistry may aid in the 
diagnosis65. 
BASALOID SQUAMOUS CELL CARCINOMA 
Basaloid squamous cell carcinoma is a poorly differentiated 
malignant epithelial tumor with small cells in lobular architecture and 
with peripheral palisading.The tumor was previously known as Large cell 
carcinoma,but was recognized as a separate entity in 2015 WHO 
classification.  
MACROSCOPY: 
The tumor presents as a grey white solid exophytic endobronchial 
growth and occasional central necrosis66.  
MICROSCOPY: 
The tumor is predominantly solid and nodular with peripheral 
palisading of multiple cell layers. The neoplastic cells are small, 
monomorphic, cuboidal or fusiform with moderately hyperchromatic 
nuclei. Mitosis is quite high. Keratin formation is occasionally seen. 
Comedo-type necrosis is common. Tumors with a keratinizing or non-
keratinising squamous cell  component ,and a basaloid component of 
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>50% is classified as basaloid squamous cell carcinoma. They express 
diffuse and strong p40 and p63 markers. 
SPINDLE CELL SQUAMOUS CARCINOMAS 
Spindle cell squamous carcinoma, also known as sarcomatoid 
carcinoma, is a tumor characterized by an appearance that simulates 
sarcoma 67 .The tumor is composed predominantly of atypical spindle 
cells with elongated nuclei, moderate amounts of cytoplasm, and 
prominent nucleoli.Focal areas  show  blending  with areas of more 
conventional squamous cell carcinoma . Spindle cell squamous 
carcinoma is characterized by the presence of keratin reactivity in the 
tumor cells, as well as by the demonstration of tonofilaments and 
desmosome-type intercellular junctions on ultrastructural microscopy68.  
 
LARGE CELL CARCINOMA 
   It is an undifferentiated non small cell carcinoma that lacks the 
cytological, architectural and immunohistochemical feature of small cell 
carcinoma, squamous cell carcinoma, adenocarcinoma. The diagnosis 
cannot be made on non resection or cytology specimens. The 2004 WHO 
classification included several subtypes that has been now moved to other 
categories ,such as basaloid carcinoma(under squamous cell 
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carcinoma),Large cell neuroendocrine carcinoma(under neuroendocrine 
tumors) and lymphoepithelioma like carcinoma(under unclassified). 
Based on the immunohistochemical expression, they are sub 
grouped into three types 
    1)Large cell carcinoma with null immunohistochemical features. 
    2)Large cell carcinoma with unclear immunohistochemical features. 
    3)Large cell carcinoma with no additional stains. 
The causative factors are the same as adenocarcinoma, example 
more common in smokers. Molecular alterations characteristic of 
adenocarcinoma (EGFR,KRAS,BRAF, and ALK fusions) are seen in 
large cell carcinoma with immunoprofiles of adenocarcinoma69.They 
share many of the genetic profiles of adenocarcinoma, squamous cell 
carcinoma, or even small cell carcinoma. Thus molecular testing is 
recommended for targeted therapy to be considered in the line of 
treatment. 
MACROSCOPY: 
Large cell carcinomas are large circumscribed solid masses, with 
necrosis being more common. 
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MICROSCOPY: 
Large cell carcinomas composed of sheets or nests of large 
polygonal cells with moderate amount of cytoplasm and vesicular nuclei 
with prominent nucleoli. It is a diagnosis of exclusion made after 
excluding the adenocarcinoma component, squamous component, small 
cell component and the expression of neuroendocrine markers is negative. 
The clear cell and rhabdoid features are not regarded as subtypes, but 
regarded as a histological feature that can occur in any type of non small 
cell lung carcinoma70.Their percentage of the total tumor should be 
documented as it is prognostically significant. 
TTF1 and p40 are regarded as useful markers which are expressed 
in morphologically undifferentiated non small cell lung carcinomas 71. 
CK7 is positive in nearly all resected undifferentiated non small cell large 
carcinomas with adenocarcinomatous profiles. Desmocollin 3 is a better 
specific squamous marker but it’s sensitivity is lower than p4071. 
The differential diagnosis of large cell carcinoma includes  
Adenocarcinoma with a more solid pattern, Non keratinizing squamous 
cell carcinoma in which intercellular bridges are sparse,adenosquamous 
carcinoma.If they show lack of specific immunohistochemical expression 
and mucin staining negativity they are classified as large cell carcinoma 
with a null phenotype.If ≥10% of the tumor cells show pleomorphic 
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features(spindle and/or giant cells), then the tumor should be classified as 
a pleomorphic carcinoma. 
 
ADENOSQUAMOUS CARCINOMA    
They show both adenocarcinoma and squamous cell carcinoma 
components, with each component constituting atleast 10%  of the tumor. 
Smoking is an associative predisposing factor. More than half of these 
patients have significant findings on chest X-ray without any symptoms. 
Adenosquamous carcinomas typically arise in the peripheral lung 
parenchyma  and the macroscopic features are that of non small cell 
carcinoma .Recent molecular studies have suggested that these mixed 
type of tumors reflect the genetic status of either of the component 
insignificant of the proportion present62.The two components may be 
separate,or merged or mingled.Only diffuse and clear positivity of TTF1 
and p40 has significance.A high grade mucoepidermoid carcinoma 
simulates adenosquamous malignancy. To  differentiate, the 
mucoepidermoid carcinoma  commonly presents with a mixture of 
mucinous and squamoid cells, a proximal exophytic endobronchial 
location, lack of keratinisation or keratin pearls, tubular or acinar pattern, 
and no overlying squamous cell carcinoma in situ72.In addition they show 
TTF1 negativity72. 
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NEUROENDOCRINE TUMORS: 
1.SMALL CELL CARCINOMA 
Small cell carcinomas are composed of small cells with scant 
cytoplasm finely granular dispersed chromatin without any nucleoli. The 
cells maybe round, oval or spindle shaped. Nuclear moulding is 
prominent. Combined small cell carcinoma includes an additional non 
small cell component i.e., adenocarcinoma, squamous cell carcinoma or 
large cell carcinoma. Among the lung cancer types, small cell carcinoma 
has a stronger association with cigarette smoking73.Small cell carcinomas 
express neuroendocrine markers and they account for the more number of 
paraneoplastic syndromes associated with lung cancer. Paraneoplastic 
syndromes include hyponatremia (increased ADH),Cushing syndrome, 
Lambort-Eaton myasthenic syndrome, peripheral neuropathy, or limbic 
encephalopathy. The high grade tumors contain the characteristic tobacco 
carcinogen-associated molecular signature i.e., abundant number of 
mutations and a high fraction of G→T translocations caused by 
polycyclic aromatic hydrocarbons, often occurring at methylated CpG 
dinucleotides74. 
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Grossly they are commonly located centrally in the major airways, 
presenting as a perihilar mass with peribronchial obstruction and nodal 
involvement. In lung parenchyma, the tumor may spread along bronchi in 
a subepithelial and radial pattern . On microscopic examination, sheet like 
densely packed small cells with scant cytoplasm and granular chromatin 
are seen. The cell size is generally less than the diameter of three small 
lymphocytes. Nucleoli are inconspicuous and has a high mitotic index 
>50%.NCAM/CD56 is the most sensitive marker75.Synaptophysin and 
chromogranin are also expressed. Rarely small cell carcinomas may occur 
in EGFR mutated adenocarcinomas, and this maybe due to development 
of resistance to tyrosine kinase inhibitors which leads to morphological 
transition76. 
Differential diagnosis includes Large cell neuroendocrine 
tumor,typical and atypical carcinoid, Ewing family of tumors, and 
metastatic tumors.High nucleo-cytoplasmic ratio and the presence of 
nucleoli favours large cell neuroendocrine type.Carcinoid, both typical 
and atypical has a mitotic rate of <2 mitosis per 2 mm2 and 2-10 mitosis 
per 2 mm2  respectively77.Ewing family of  tumors has diffuse 
membranous positivity for CD99 and usually lack keratin expression. 
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2.LARGE CELL NEUROENDOCRINE CARCINOMA 
 Large cell neuroendocrine carcinoma was classified as a variant of 
large cell carcinoma in the second and third WHO classification. They 
share the same molecular characteristics, etiology, carcinogenesis, tumor 
suppressor gene inactivation and oncogene drivers as the same as that of 
small cell carcinoma. It is more common in smokers same as small cell 
type. A pluoripotent stem cell of epithelial  origin with neuroendocrine 
differentiation potential has been proposed as the cell of  
origin78.Combined large cell neuroendocrine carcinoma with non small 
cell components occurs with the same frequency as that of small cell 
carcinoma. 
Large cell neuroendocrine carcinoma is a high grade malignant 
tumor, located more commonly in the peripheral lung. They are large 
masses, has a predilection towards upper lobes. Macroscopically the 
tumor is circumscribed with a tan-red cut surface and foci of 
necrosis79.The neoplasm may invade the pleura, chest wall, and adjacent 
structures. Paraneoplastic syndromes are not common. 
They are composed of large cells arranged in organoid nests, 
trabeculae, and solid patterns. The cells are large with moderate to 
abundant cytoplasm and high nucleo-cytoplasmic ratio. The presence of 
distinct nucleoli distinguishes it from small cell carcinoma. Mitosis 
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should be high,>10 mitosis per 2mm2.Large punctuate zones of necrosis 
is seen. Neuroendocrine differentiation should be confirmed by 
immunohistochemical markers such as chromogranin, synaptophysin and 
NCAM. One positive marker is enough if the staining is distinct in >10% 
of tumor cells. Distinction from small cell carcinoma can be made based 
on cytology i.e., prominent nucleoli, abundant cytoplasm, cell size. 
Carcinoid is distinguished by the presence of mitosis. Patients have a 
poor prognosis than with other non small cell carcinoma. 
3.CARCINOID 
Carcinoid are subtyped into typical and atypical. They are low and 
intermediate grade tumors respectively. Risk factors include family 
history, white females and non white males80.Atypical carcinoid has a 
known association with smoking.It was historically thought to arise from 
pulmonary neuroendocrine(kulchitsky) cells and some cases has been 
seen arising from a  preinvasive lesion like diffuse idiopathic pulmonary 
meuroendocrine cell hyperplasia81. Pulmonary carcinoids display the 
lowest somatic mutation rate among lung malignancies. The only 
significant mutations affect the chromatin remodeling gene family MEN1 
in mutual exclusion with PSP182 and they were more frequent in atypical 
carcinoids.                
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Carcinoids can be seen anywhere from the trachea to the 
bronchioles. They most commonly arise in the main airways. These 
central carcinoids are well circumscribed, sessile or pedunculated masses, 
filling the bronchial cavity. Some of them arise in the periphery and they 
are aymptomatic, which are discovered incidentally. Nodular 
neuroendocrine proliferations measuring < 5  mm are classified as 
tumorlets83. 
Microscopically Typical carcinoid are characterized by organoid 
and trabecular patterns. Mixture of other patterns like rosette formation, 
pseudoglandular, papillary, or spindle cell pattern may also be seen. 
Individual tumor cells are usually polygonal, uniform in appearance with 
moderate to abundant cytoplasm and fine granular chromatin with 
inconspicuous nucleoli. Background may contain vascularised stroma, 
with extensive hyalinization, cartilage or bone formation . 
Atypical carcinoid shares the same histological features as that of 
typical carcinoid except for mitotic rate(2-10 per 2 mm2) and necrosis. 
Mitosis should be counted in the area of high mitotic activity with viable 
tumor cells. 
  Neuroendocrine markers like chromogranin,synaptophysin,CD56 
are found to  be positive. High molecular weight cytokeratins are 
typically negative in carcinoids. however these do not differentiate typical 
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from atypical carcinoid. Distinction between typical carcinoid from 
atypical carcinoid  is considered to be an important prognostic factor. 
Atypical carcinoid is more likely to metastasize and has a worse 
prognosis. 
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                        MATERIALS AND METHODS 
 
STUDY DESIGN: 
             Prospective study 
STUDY PERIOD: 
             May  2017 to June 2018 
PLACE OF STUDY: 
            Department of Pathology, Coimbatore Medical College, 
Coimbatore. 
INCLUSION CRITERIA: 
1.Age            - 20-80 years. 
2.Gender       - Males and Females. 
3.Patients diagnosed with Non small cell carcinoma of lung 
histologically. 
EXCLUSION CRITERIA: 
1. Antenatal patients. 
2. Biopsy specimens with inadequate tissue. 
3. Patients diagnosed with other histological types like small cell 
carcinoma,Neuroendocrine tumor,metastasis. 
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4. Patients with other organ known malignancies. 
5.  HIV. 
During the period of May 2017 to June 2018, the patients visiting 
Thoracic Medicine op at Coimbatore Medical College Hospital in whom 
lung biopsies are taken for mass lesion were studied. Their clinical 
features were noted. The lung biopsies were received in 10%neutral 
buffered saline solution in the department of pathology, Coimbatore 
Medical college. After fixation they were taken up for processing. The 
processed tissue was embedded in paraffin wax and sections were taken. 
After incubation, Hematoxylin and eosin staining was performed on the 
slides. Sections were studied under light microscope. All the reported 
Non small cell    carcinomas of the lung were immunostained with EGFR 
antibody using monoclonal EGFR rabbit antibody. The staining was done 
as per the following protocol. 
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METHODS OF IMMUNOHISTOCHEMISTRY 
METHOD: 
              Two-step indirect technique 
PRINCIPLES OF THE PROCEDURE: 
The technique is based on the detection of antigens in the cells and 
tissues with the help of two-step process: 
    1. Specific epitopes are used to bind the primary antibody. 
    2. Followed by calorimetric reaction, which detects the antigen-
antibody binding. 
REAGENTS USED IN IMMUNOHISTOCHEMISTRY  
1. Peroxide block:3% hydrogen peroxide in water. 
2. Power block reagent: A highly effective universal protein blocking 
reagent. Contains casein and propriety additives in PBS with 
15Mm sodium azide. 
3. Chromogen:DAB-3,3’-diaminobenzidine. 
4. Liquid DAB substrate:Tris buffer containing peroxide and 
stabilizers.  
5. Super Enhancer Reagent. 
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6. Poly-HRP Reagent. 
7. Counterstain : Mayer’s  Hematoxylin. 
8. Buffer solutions. 
a) TRIS BUFFER:(Ph-7.6) 
        TRIS buffer salt              :   0.605 gm 
        Sodium Chloride             :   8 gm 
        Distilled water             :   1000 ml 
1N Hydrochloric acid      :   3 ml 
b) CITRATE BUFFER:(Ph-6.0) 
        Trisodium Citrate            :    2.94 gm 
        Distilled water                 :    1000 ml 
        1N Hydrochloric acid     :    5 ml 
c) TRIS EDTA:(Ph-9.0) 
       TRIS Buffer salt              :    6.05 gm 
       Disodium EDTA             :    0.744 gm 
       Distilled water                :    1000 ml 
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PROCEDURE: 
1. Deparaffinise the sections in xylene for 30 minutes. 
2. Wash in absolute alcohol for 5 minutes with 2 changes. 
3. Wash in Tap water for 10 minutes. 
4. Rinse in distilled water for 5 minutes. 
5. Antigen retrieval is done by placing the slides in appropriate buffer 
solutions in microwave:Medium-10 minutes and high-10 minutes. 
6. Cool to room temperature and rinse the slides in distilled water. 
7. Wash in TBS buffer for 5 minutes with 2 changes. 
8. Treat the peroxide block for 10 minutes. 
9. Wash in TBS buffer for 5 minutes with 2 changes. 
10. Treat with power block for 10 minutes. 
11. Drain the slides and cover with primary antibody(supplied from 
DAKOCYTOMATION). 
12. Wash in TBS buffer for 5 minutes with 2 changes. 
13. Cover the slides with super enhancer for 30 minutes. 
14. Wash in TBS buffer for 5 minutes with 2 changes. 
15. Apply poly HRP reagent and leave for 30 minutes. 
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16. Wash in TBS buffer for 5 minutes with 2 changes. 
17. Treat with DAB chromogen with substrate buffer for 5 to 8 
minutes. 
18. Wash in TBS buffer for 5 minutes with 2 changes 
19. Wash the slides in tap water for 5 minutes 
20. Counterstain with Mayer’s Hematoxylin for 1 minute. 
21. Wash in tap water for 5 minutes. 
22. Air dry and mount in DPX. 
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  The slides are scored based on the cytoplasmic and/or membrane 
staining intensity of the tumor cells as follows84. 
Staining pattern Score 
No staining or faint staining in less than 10% of the tumor 
cells(negative) 
0 
Faint membrane and/or cytoplasmic staining in greater than 
10% of the tumor cells. 
1 
 
Moderate membrane staining and/or cytoplasmic staining. 2 
Strong membrane and/or cytoplasmic staining 3 
 
The observations are recorded,tabulated,and statistical analysis was 
performed. 
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OBSERVATION AND RESULTS 
 
              The present study was a prospective study conducted in the 
Department of Pathology, Coimbatore Medical College Hospital. A 
sample size of 30 cases were studied.The samples included lung biopsy 
specimens obtained by imaging studies guidance and bronchoscopic 
guidance. The study period was from MAY 2017 TO JUNE 2018. 
Ethical clearance for the study was obtained from the committee of 
Coimbatore Medical College, Coimbatore. 
            EGFR mutations in Non small cell lung carcinomas by 
Immunohistochemistry was evaluated and compared with those in the 
literature. 
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Table 1: 
Mean age of the study 
 
 N Minimum Maximum Mean±SD 
AGE 30 45 85 62.70±9.3 
 
    In this study,  the non small cell lung canrcinomas occur 
predominantly in the age group ranging from 45 to 85 years. The mean 
age of the patient is 62.7years. 
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Table 2:  
Gender distribution in Non-small cell Lung Cancer 
Gender Frequency Percent (%) 
Male 25 83.3 
Female 5 16.7 
Total 30 100.0 
 
Chart 1: 
Gender distribution in Non-small cell Lung Cancer 
 
In this present study,non small cell carcinomas of lung are found to be 
more prevalent in males(83%) 
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Table 3:  
Smoking history in Non Small cell Lung Cancer 
Smoking history Frequency Percent (%) 
NON SMOKER 11 36.7 
SMOKER 19 63.3 
Total 30 100.0 
 
Chart 2: 
Smoking history in Non Small cell Lung Cancer 
 
 
 
The present study showed a significant association of non small cell lung 
carcinomas in smokers(63.3%).However the incidence of non small cell 
carcinomas in non smokers is found to be increasing. 
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Table 4:  
HPE DIAGNOSIS 
HPE DIAGNOSIS Frequency Percent (%) 
Adenocarcinoma 11 36.7 
Lepidic  adenocarcinoma 2 6.7 
Squamous cell carcinoma 17 56.7 
Total 30 100.0 
 
Chart 3:  
HPE DIAGNOSIS 
 
 
 
Squamous cell carcinoma is found to be the most common histological 
subtype of non small cell carcinoma, followed by adenocarcinoma. 
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Table 5:  
Association of gender with HPE diagnosis 
 
Gender 
HPE diagnosis P value 
Adenocarcinoma Lepidic adenocarcinoma 
Squamous 
cell 
carcinoma 
 
.001* 
Male 8(32.0%) 0(0.0%) 17(68.0%) 
Female 3(60.0%) 2(40.0%) 0(0.0%) 
*-STATISTICALLY SIGNIFICANT (P<0.05) 
 
Chart 4:  
Association of gender with HPE diagnosis 
 
 
There appears to be a significant correlation between male gender,higher 
age and squamous cell carcinoma,which was statistically significant in 
this prospective study. 
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Table 6: 
Association of smoking status with HPE diagnosis 
 
Smoking 
status 
HPE diagnosis P value 
Adenocarcinoma Lepidic adenocarcinoma 
Squamous 
cell 
carcinoma 
 
.143 
Non 
smoker 
3(27.3%) 2(18.2%) 6(54.5%) 
Smoker 8(42.1%) 0(0.0%) 11(57.9%) 
 
Chart 5: 
Association of smoking status with HPE diagnosis 
 
 
No statistically significant association was found between smoking status 
and the histopathological subtype. 
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                                                    Table 7: 
Association of gender with EGFR expression 
 
Gender 
EGFR EXPRESSION 
P 
value 
1+ 2+ 3+ NEGATIVE 
 
.529 
Male 6(24.0%) 4(16.0%) 13(52.0%) 2(8.0%) 
Female 0(0.0%) 1(20.0%) 4(80.0%) 0(0.0%) 
 
Chart 6: 
Association of gender with EGFR expression 
 
 
                                 1+                   2+                3+            Negative 
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Table 8: 
Association of smoking status with EGFR expression 
 
Smoking 
status 
EGFR EXPRESSION P value 
1+ 2+ 3+ NEGATIVE 
 
.759 
Non 
smoker 1(9.1%) 2(18.2%) 7(63.6%) 1(9.1%) 
Smoker 5(26.3%) 3(15.8%) 10(52.6%) 1(5.3%) 
 
Chart 7: 
Association of smoking status with EGFR expression 
 
 
                                 1+                   2+                3+            Negative 
 
 Our present study showed no significant association between 
EGFR  expression and demographic factors, such as gender, smoking 
status. 
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Table 9:  
EGFR EXPRESSION 
EGFR EXPRESSION Frequency Percent (%) 
1+ 6 20.0 
2+ 5 16.7 
3+ 17 56.7 
NEGATIVE 2 6.7 
Total 30 100.0 
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Chart 8:  
EGFR EXPRESSION 
 
 
 
                       1+                   2+                   3+                  Negative 
 
                  The staining intensities are graded as per the scoring system 
discussed above84.Strong cytoplasmic and membranous staining(3+) was 
observed in 17 cases out of 30 cases(56.7%),2+ in 5 cases,1+ in 6 cases,0 
in 2 cases. 
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Table 10: 
Association of HPE diagnosis with EGFR expression 
 
HPE diagnosis 
EGFR EXPRESSION P value 
1+ 2+ 3+ NEGATIVE 
 
 
 
.156 
Adenocarcinoma 0(0.0%) 3(27.3%) 8(72.7%) 0(0.0%) 
Lepidic 
adenocarcinoma 
0(0.0%) 0(0.0%) 2(100.0%) 0(0.0%) 
Squamous cell 
carcinoma 
6(35.3%) 2(11.8%) 7(41.2%) 2(11.8%) 
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Chart 9 : 
Association of HPE diagnosis with EGFR expression 
 
 
 
 
 
In this study, we found that no association was observed between 
EGFR expression and Histological subtype. However EGFR expression 
is more common in adenocarcinomas.  
  
 
 
 
 
 
 
 
 
 
 
 
COLOUR PLATES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure.1: H&E Section Showing Glandular Pattern in                
Adenocarcinoma (100x) 
 
Figure.2: H&E Section Showing Malignant columnar Cells In Glandular 
Pattern in Adenocarcinoma (400x) 
  
 
Figure.3:Immunohistochemical  stain of  EGFR In Adenocarcinoma 
Showing Moderate Membranous And Cytoplasmic Positivity (2+)(100x) 
 
Figure.4: Immunohistochemical stain of  EGFR In Adenocarcinoma 
Showing Strong Membranous And Cytoplasmic Staining (3+) (100x)  
  
 
Figure.5: Immunohistochemical staining of EGFR In Adenocarcinoma 
Showing  Strong Cytoplasmic And Membranous Staining (3+) (400x) 
 
Figure : 6. H&E Section Showing Malignant Columnar Cells in Lepidic 
Pattern (400x) 
  
 
Figure.7: Immunohistochemical Stain of EGFR showing strong 
membranous and cytoplasmic staining (3+) (100x) 
 
Figure.8: Immunohistochemical Stain of EGFR showing strong 
membranous and cytoplasmic staining (3+) (400x) 
  
 
Figure.9. H&E Section showing Keratin Pearl formation in Squamous 
Cell Carcinoma(100x) 
 
Figure.10: H&E Section showing Malignant Squamous Cells in               
Sheets (400x) 
  
 
Figure.11: Immunohistochemical Stain of EGFR showing Faint 
Cytoplasmic staining in Squamous Cell Carcinoma (1+) (400x) 
 
Figure.12: Immunohistochemical stain of EGFR showing moderate 
cytoplamic and membranous staining in squamous cell carcinoma (2+) 
(400x) 
  
 
Figure.13: Immunohistochemical stain of EGFR showing strong 
cytoplamic and membranous staining in squamous cell carcinoma (3+) 
(100x) 
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DISCUSSION 
 
Lung cancer is the most common cause of cancer related deaths  
worldwide. Major Histopathological classification includes Non small 
cell carcinoma, small cell carcinoma, Neuroendocrine and few others.  
Growth ,proliferation ,differentiation ,angiogenesis and apoptosis are 
the most important features of cells which are altered by cancer cells. 
EGFR plays a important role in exhibiting these features. Regarding 
the significance of EGFR in non small cell lung carcinomas, the behavior 
of the cancer cells could be affected by EGFR expression level85.  
The present study is done to evaluate epidermal growth factor 
receptor by immunohistochemistry in non small cell lung carcinomas. 
30 cases of lung biopsy specimens during the period from May 
2017 to  June 2018 were studied. Statistical data analysis of EGFR 
expression in non small cell carcinomas with regards to age, sex, personal 
habits and histological subtype were studied and compared with those in 
the literatutre. 
Several clinical studies have been conducted worldwide on the 
importance of EGFR signaling pathway in non small cell lung 
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carcinomas. Those studies aimed to clarify the association between EGFR 
expression and presenting features of non small cell carcinomas, which 
includes prognosis, tumor histology, metastasis and demographic factors. 
In many studies EGFR expression have been evaluated by 
immunohistochemistry and conflicting results were obtained. 
The present study showed that the peak incidence of lung tumors 
occurred in the age group ranging from 45 -85 years.The overall mean 
age of patients with non small cell carcinomas is 62.7 years. (Table.1) 
 There was a male predominance in the incidence of non small cell 
lung carcinomas(83.3%).However it is a global observation that lung 
carcinoma has a higher incidence in males than in females.(Table.2) 
           Non small cell lung  carcinomas occur more commonly in smokers 
which is  observed in the current study(63.3%).However non smokers has 
an incidence of non small cell lung carcinoma in 36.7%. Sadik M, Cemile 
K, et al.,(2014)86reviewed cases of non small cell lung carcinoma and 
they found that 83.8 % of patients are in smokers and 16.2% in non 
smokers.(Table.3) 
In the present study,out of 30 cases, Squamous cell carcinoma was 
the most common histological type of non small cell  carcinomas (56.7%) 
followed by adenocarcinoma(36.7%).Lepidic adenocarcinoma, a variant 
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of adenocarcinoma constitutes about 6.7% of the 30 non small cell 
carcinoma samples studied.(Table-4). 
In a study conducted by  Kaur H,Sehgal I S,Bal A., et al.,87done at 
Postgraduate institute of medical sciences, chandigarh, they showed an 
increasing incidence of adenocarcinoma when compared with the 
previous study done at the same institute. Thus they showed an equal 
incidence of squamous cell carcinoma and adenocarcinoma(36.4% each) 
due to an decrease in non small cell carcinoma-not otherwise specified. 
In the current study, Squamous cell carcinoma is the most common 
histological subtype in males(68%).A correlation between histological 
type and sex was observed in this study which was considered 
statistically significant.(p value-0.001).A study conducted by Kaur 
H,Sehgal I S,Bal A.,et al87 showed an association between higher 
age,male gender and squamous histology.(Table.5) 
In this present study there was no statistically significant 
association between smoking history and the histopathological subtype of 
non small cell lung cancer. But the study conducted by Kaur H, Sehgal I 
S,Bal A.,et al87 showed that there was a greater prevalence of squamous 
cell carcinoma in smokers and the frequency of squamous cell carcinoma 
was the lowest in non smokers.(Table.6) 
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             Conflicting results exist on the association between EGFR 
expression level and factors such as demographic factors, tumor 
histology. Most of the studies conducted on this association do not reveal 
any significance88.However a study conducted in Poland in 2004 showed 
an association between EGFR expression and the age of Non small cell  
lung carcinoma patients89.But our findings do not indicate any such 
association between EGFR expression and demographic factors. 
(Table.7,8)     
               It was observed in this study that there was no significant 
association between tumor histology and EGFR expression. It was 
observed that EGFR expression was more prevalent in adenocarcinoma 
than other tumor subtypes. A study performed by Pfeiffer P,Nexo E,              
et al.,90in denmark in the late 1990’s showed  that EGFR expression level 
was significant in squamous cell carcinoma than other tumor subtypes.   
A study conducted by Basiri R,Jaffarian AH, et al.,91 found no association 
between tumor histology and EGFR expression level. However they also 
observed that EGFR expression was more prevalent in adenocarcinomas 
than other tumor subtypes similar to this present study.(Table 10)In 
general we attributed observed difference to limitations in subject 
selection,that is if all the subjects during this period of time has been 
included,it might  have ended with a varied result. 
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The pattern of IHC positivity is also important. Some studies 
showed a significant association between the EGFR expression level and 
the survival time of the patients by different scoring methods of the 
staining intensity. Our present study showed 3+ grading staining intensity 
in 17 cases,2+ in 5 cases,1+ in 6 cases and negative or 0 in 2 cases.0 was 
considered as negative and 1+,2+,3+ were considered as positive cases 
based on the study conducted by Jain D,Iqbal S, et al.,92 conducted at All 
India Institute of Medical Sciences, New Delhi.(Table.9) Allo et al 93 
showed a small yet significant false positive rates in small biopsies. It has 
been observed that false positive are associated with 1+ staining. 
However further studies are required to determine the exact false 
positivity with this antibody. This study recommends 2+ and 3+ cases can 
be considered true positives whereas 1+ cases must be confirmed with 
molecular testing. The association between survival rate of the patients 
and EGFR antibody staining intensity was not dealt in this study  since 
the data are obtained from paper based medical records. Thus further 
clinical analysis and interpretations could not be made. 
Molecular analysis was done in the study conducted by Jain 
D,Iqbal S, et al.,92 to compare the EGFR mutation expression by 
Immunohistochemistry . The findings of EGFR expression by 
Immunohistochemistry showed a concordance of 85.7 percent of tested 
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biopsy samples with the molecular analysis. The observed specificity was 
high, which ranged from 92 to 100 percent. Routinely the most frequently 
received specimen for the diagnosis of lung carcinoma is a small biopsy 
or a cytology. Thus molecular testing may fail in scant cellularity cases. 
Other drawbacks are the high cost, and inavailaibity of experts in low 
resource settings.                                    
The major limitations of this study includes the following. 
1)  Molecular analysis was not done to establish the accurate 
concordance and to rule out false positivities.. 
2) The lack of information about the clinical and prognostic nature of 
the mutation positive patients since the data are obtained from 
paper based medical records. 
However Immunhistochemistry can be routinely used as a potential tool 
at the time of diagnosis because of their high specificity. Morover it has 
an added advantage of low cost, reduced turnaround time, easy 
availability and rapid interpretation by pathologist. They are also helpful 
in low cellularity samples and preventing the contamination of tumor by 
normal tissue in molecular testing. 
 
78 
 
SUMMARY AND CONCLUSION 
Non small cell carcinomas of the lung needs specific histologic 
subtyping for  the role of targeted therapy.  
EGFR mutation is one of the common genetic alteration which gets 
its significance by undergoing pharmacological inhibition by targeted 
drugs. 
         EGFR mutation study by Immunohistochemistry in non small cell 
lung carcinomas is a  prospective study done at the Department of 
Pathology, Coimbatore Medical College Hospital, Coimbatore over a 
period of one year from  May 2017 to June 2018.This preliminary study 
was done to assess the percentage positivity of IHC using EGFR mutation 
specific antibodies in non small cell lung carcinoma samples diagnosed 
on histopathology.   
        Out of the 30 cases,17 cases had a strong membranous and 
cytoplasmic(3+)staining,2+grading in 5 cases and 1+ in 6 cases. EGFR 
was negative in 2 cases(6.7%). 
       Though there was no statistically significant association observed 
between EGFR expression and tumor histological subtype, It was found 
that EGFR positivity is more common in Adenocarcinomas 
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Thus  EGFR mutation analysis by Immunohistochemistry can be 
used as an initial, rapid and cost effective tool especially in our laboratory 
setup where molecular analysis tools are limited. It is also useful to avoid 
the problems of molecular studies in small low cellularity samples. It 
seems that using standardized scoring system in Immunohistochemistry 
analysis of EGFR mutations could probably yield more reliable results. 
           Thus we conclude that EGFR mutation studies by 
immunohistochemistry can be a better tool to be used as a guidance for 
targeted therapy.  
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APPENDIX I 
 
CLINICAL PROFORMA 
  
COIMBATORE MEDICAL COLLEGE 
DEPARTMENT OF PATHOLOGY 
COIMBATORE 
 
Particulars of the patient: 
Name;                                                               IP/OP number: 
Age(years):                                                       Ward No: 
Sex:                                                                   Occupation: 
Address: 
 
Presenting Complaints and Duration: 
Cough 
Dyspnoea 
Chest pain 
Hemoptysis 
Fever 
Loss of Weight/Loss of appetite 
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Family History: 
Malignancy+/- 
 
Personal history: 
Smoker+/- 
No of Cigarettes per day 
 
General Physical Examination: 
Conscious/Built: 
Pallor: 
Jaundice: 
Cyanosis: 
Clubbing: 
Lymphadenopathy: 
Pulse rate/respiratory rate: 
Systemic examination: 
RS: 
CVS: 
PER ABDOMEN: 
CNS: 
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Clinical diagnosis: 
 
Radiological findings: 
 
 
 
Microscopic findings; 
Histopathology: 
Immunohistochemistry: 
 
Final diagnosis: 
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APPENDIX – II 
MASTER CHART 
HPE NO- AGE/SEX SMOKER/NON SMOKER CT FINDINGS HPE DIAGNOSIS EGFR EXPRESSION 
540/17  45 /MALE SMOKER 
LEFT LOWER LOBE MASS WITH 
PLEURAL EFFUSION 
SQUAMOUS CELL 
CARCINOMA 
1+ 
582/17 59/MALE SMOKER RIGHT UPPER LOBE CONSOLIDATION 
SQUAMOUS CELL 
CARCINOMA 
3+ 
854/17 60/ MALE SMOKER LEFT UPPER LOBE MASS ADENOCARCINOMA 3+ 
818/17 45/ MALE NON SMOKER LARGE MASS IN LEFT UPPER LOBE  
SQUAMOUS CELL 
CARCINOMA 
1+ 
821/17 60/FEMALE NON SMOKER 
RIGHT LOWER LOBE MASS WITH 
MULTIFOCAL CONSOLIDATION 
ADENOCARCINOMA 3+ 
834/17 74/ MALE NON SMOKER RIGHT HILAR AND LOWER LOBE MASS 
SQUAMOUS CELL 
CARCINOMA 
3+ 
983/17 65/ MALE SMOKER 
LEFT LOWER LOBE MASS WITH 
MEDIASTINAL LYMPHNODES 
ADENOCARCINOMA 3+ 
1047/17 52/ MALE NON SMOKER LEFT UPPER LOBE MASS 
SQUAMOUS CELL 
CARCINOMA 
3+ 
1072/17 67/FEMALE NON SMOKER 
RIGHT UPPER LOBE AND MIDDLE LOBE 
MASS 
ADENOCARCINOMA 3+ 
1156/17 63/ MALE SMOKER 
LEFT LOWER LOBE MASS WITH 
PLEURAL EFFUSION 
ADENOCARCINOMA 2+ 
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HPE NO- AGE/SEX SMOKER/NON SMOKER CT FINDINGS HPE DIAGNOSIS EGFR EXPRESSION 
1202/17 48/ MALE NON SMOKER LEFT UPPER LOBE MASS 
SQUAMOUS CELL 
CARCINOMA 
2+ 
1229/17 60/ MALE SMOKER RIGHT UPPER LOBE MASS 
SQUAMOUS CELL 
CARCINOMA 
1+ 
1296/17 70/ MALE SMOKER RIGHT UPPER LOBE MASS 
SQUAMOUS CELL 
CARCINOMA 
2+ 
1456/17 56/ MALE SMOKER LEFT HILAR MASS 
SQUAMOUS CELL 
CARCINOMA 
1+ 
1465/17 52/ MALE SMOKER 
RIGHT LOWER LOBE MASS WITH 
CONSOLIDATION 
SQUAMOUS CELL 
CARCINOMA 
1+ 
3036/17 61/ MALE NON SMOKER LEFT UPPER LOBE MASS 
SQUAMOUS CELL 
CARCINOMA 
NEGATIVE 
3045/17 72/ MALE NON SMOKER 
LEFT LOWER LOBE MASS WITH 
PLEURAL EFFUSION 
SQUAMOUS CELL 
CARCINOMA 
3+ 
3085/17 60/ MALE SMOKER RIGHT HILAR AND LOWER LOBE MASS 
SQUAMOUS CELL 
CARCINOMA 
NEGATIVE 
3089/17 63/ MALE SMOKER 
RIGHT UPPER LOBE MASS WITH HILAR 
NODE ENLARGEMENT 
ADENOCARCINOMA 3+ 
3787/17 66/ MALE SMOKER 
RIGHT UPPER LOBE MASS WITH 
EMPHYSEMATOUS CHENGES 
ADENOCARCINOMA 3+ 
4062/17 70/ MALE SMOKER LEFT UPPER LOBE MASS ADENOCARCINOMA 3+ 
4485/17 65/ MALE SMOKER 
RIGHT MIDDLE AND LOWER LOBE 
MASS 
ADENOCARCINOMA 3+ 
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HPE NO- AGE/SEX SMOKER/NON SMOKER CT FINDINGS HPE DIAGNOSIS EGFR EXPRESSION 
4488/17 75/ MALE SMOKER RIGHT UPPER LOBE MASS 
SQUAMOUS CELL 
CARCINOMA 
3+ 
4511/17 85/ MALE SMOKER 
RIGHT UPPER LOBE MASS WITH 
ENLARGED HILAR NODES 
SQUAMOUS CELL 
CARCINOMA 
3+ 
584/18 70/FEMALE NON SMOKER LEFT LOWER LOBE MASS ADENOCARCINOMA 2+ 
598/18 51/ MALE SMOKER RIGHT UPPER LOBE MASS 
SQUAMOUS CELL 
CARCINOMA 
1+ 
2040/18 65/FEMALE NON SMOKER RIGHT LOWER LOBE MASS 
LEPIDIC 
ADENOCARCINOMA 
3+ 
2468/18 72/ MALE SMOKER RIGHT UPPER LOBE MASS ADENOCARCINOMA 2+ 
2495/18 70/ MALE SMOKER RIGHT LOWER LOBE MASS 
SQUAMOUS CELL 
CARCINOMA 
3+ 
2497/18 60/FEMALE NON SMOKER LEFT UPPER LOBE MASS 
LEPIDIC 
ADENOCARCINOMA 
3+ 
 
